Retrospective Analysis between Three Weekly and Weekly Cisplatin Concurrently with Radiotherapy for Patient with Post-Operative High Risk Squamous Cell Carcinoma of Oral Cavity
Downloads
Background: The aim of this study is to compare the outcomes of postoperative adjuvant concomitant chemo radiotherapy using two different schedules of cisplatin received by patients with high risk squamous cell carcinoma(SCC) of oral cavity.
Methods: A retrospective study of 44 patients with high risk oral SCC were analyzed from January 2017 to December 2019. Patients were divided into two treatment groups receiving either 100mg/m2 every 3weeks (arm A) or 40mg/m2 cisplatin once in a week (arm B). All the patients were irradiated 60Gy.
Results: out of the 44 eligible patients, 22 were assigned to arm A and 22 to arm B. Both groups received same mean doses of radiation and cisplatin. 68.2% in arm A and 52.7% in arm B (p value=0.0026received ≥ 200mg/m2 of total cisplatin with statistical difference. The overall toxicity was greater in arm B (p =0.621) and the grade 3 toxicity is slightly higher in arm B, but statistically not significant.
Conclusions: Three weekly high dose cisplatin showed high compliance and similar acute toxicity compared to weekly low dose cisplatin and is feasible for administration in outpatient settings with low rate of hospitalization. Advance post op case of oral cavity needs both chemotherapy and radiotherapy for better survival and outcome. It needs larger study to demonstrate which chemotherapy schedule is slandered of care.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350:1937–1944
Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, and Lefebvre JL: Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005, 27:843–850.
Geeta SN, Padmanabhan TK, Samuel J, Pavithran K, Iyer S, Kuriakose MA: Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. J Cancer Res Ther 2006, 2:100–104.
Ho KF, Swindell R, Brammer CV: Dose intensity comparison between weekly and 3-weekly cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New cross hospital, wolverhampton. UK. Acta Oncol 2008, 47:1513–1518.
Uygun K, Bilici A, Karagol H, Caloglu M, Cicin I, Aksu G, Fayda M, Uzunoglu S: The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2009, 64:601–605.
Marcu L, Bezak E, Olver I: Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach. Phys Med Biol 2006, 51:3625–3637.
Marcu L, van Doorn T, Olver I: Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer–a review of their cooperation. Acta Oncol 2003, 42:315–325.
All Content should be original and unpublished.
